to manage diabetes better.
Our vision at Roche Diabetes Care is to help people with diabetes everywhere in the world think less about their daily diabetes routine so they can experience true relief, day and night.
Diabetes is a complex condition that requires smart solutions to manage this health challenge effectively. With more than 40 years of experience and over 5,500 employees in more than 100 markets, Roche Diabetes Care is dedicated to advance care and foster sustainable structures to counter the diabetes epidemic.
As a global leader in integrated Personalised Diabetes Management (iPDM), Roche Diabetes Care has been pioneering innovation for more than 40 years – spanning from the first introduction of at-home testing, further simplified and strip-free blood glucose monitoring, to offering the first FDA approved bolus advisor.
Under the brands RocheDiabetes, Accu-Chek and mySugr, comprising glucose monitoring, insulin delivery and digital solutions, we unite with our partners to facilitate integrated Personalised Diabetes Management. Doing so, we aim to support people with diabetes and those at risk to reach their therapy goals and spend more time in range.
With thought leaders around the world, including people with diabetes, caregivers, healthcare providers, and payers, we share the goal to transform provision of care. By building and collaborating in an open ecosystem, we drive insights and innovation to enable a deeper understanding of the disease, leading to personalised and effective therapy adjustments. For better outcomes and true relief.
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.
Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.
Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the eleventh consecutive year, Roche has been recognised as one of the most sustainable companies in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).
The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2018 employed about 94,000 people worldwide. In 2018, Roche invested CHF 11 billion in R&D and posted sales of CHF 56.8 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.
For more information, please visit www.roche.com